Expert Opinion on Drug Safety
Volume 21, 2022 - Issue 11
Original Research
Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
Kohei Kakua Department of Medicine, Kawasaki Medical School, Okayama, Japan
https://orcid.org/0000-0003-1574-0565View further author information
https://orcid.org/0000-0003-1574-0565View further author information, Kazuhiro Yamamotob Department of Cardiovascular Medicine, and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Tottori, Japanhttps://orcid.org/0000-0003-2766-4213View further author information
https://orcid.org/0000-0003-2766-4213View further author information, , & Daisuke Nittac Medicine Division, Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-5881-1533View further author information
https://orcid.org/0000-0001-5881-1533View further author information